Legend Biotech Unveils Promising CAR-T Therapy Data at ASCO and EHA

Legend Biotech ( (LEGN) ) has shared an update.

On May 22, 2025, Legend Biotech announced new data presentations at major conferences, including ASCO and EHA, highlighting the efficacy of CARVYKTI® in treating multiple myeloma. The data includes long-term survival outcomes from the CARTITUDE-1 study and improved progression-free survival from the CARTITUDE-4 study. Additionally, preliminary results from Phase 1 studies on solid tumors, such as lung and gastric cancers, were shared, showcasing Legend Biotech’s expanding pipeline and reinforcing its leadership in the cell therapy market.

The most recent analyst rating on (LEGN) stock is a Buy with a $80.00 price target. To see the full list of analyst forecasts on Legend Biotech stock, see the LEGN Stock Forecast page.

Spark’s Take on LEGN Stock

According to Spark, TipRanks’ AI Analyst, LEGN is a Neutral.

Legend Biotech’s overall score reflects strong revenue growth and strategic plans for profitability, but is tempered by current financial losses and negative technical indicators. The positive outlook from the earnings call adds optimism, but cash flow issues and valuation concerns weigh down the score.

To see Spark’s full report on LEGN stock, click here.

More about Legend Biotech

Legend Biotech Corporation is a global leader in cell therapy, focusing on developing innovative treatments for oncologic and hematologic conditions. The company is known for its CAR-T cell therapy products, particularly CARVYKTI®, which targets multiple myeloma and other cancers.

Average Trading Volume: 1,490,003

Technical Sentiment Signal: Sell

Current Market Cap: $5.35B

Learn more about LEGN stock on TipRanks’ Stock Analysis page.